This bill denies tax deductions to employers for expenses related to two specific services: (1) reimbursing employees for travel to obtain an abortion, and (2) covering gender transition procedures for a minor child (under age 18). It directly affects employers who provide health benefits or reimbursements for these services, making such costs non-deductible for tax purposes. Key provisions define "gender transition procedure" broadly to include medical/surgical services, puberty-blocking drugs, and cross-sex hormones, with limited exceptions for medically verified disorders of sex development or complications from prior procedures. The law would take effect for taxable years after enactment.
This bill establishes minimum nurse staffing requirements for nursing homes participating in Medicare and Medicaid. It requires facilities to provide 24-hour registered nurse coverage (transitioning from 8-hour daily coverage within 180 days of enactment) and maintain a minimum of 3.48 hours of nursing care per resident daily. The bill mandates a study every four years to review staffing standards based on resident needs and safety data, with findings informing future regulations. Additionally, it directs states to use a portion of collected civil penalties to fund workforce programs like student loan repayment and career pathway development for nursing home staff.
The PHIT Act of 2025 (S 1144) allows taxpayers to deduct certain fitness expenses as medical costs on federal income taxes. It covers gym memberships, exercise classes, and fitness equipment (up to $1,000 per person annually, or $2,000 for joint filers), provided the expenses are exclusively for physical activity. Equipment must be used solely for exercise (e.g., athletic shoes worn only for activity), and facilities must meet strict criteria like excluding golf/sailing and complying with anti-discrimination laws. The bill aims to reduce financial barriers to healthy habits by making these costs tax-deductible for eligible taxpayers who itemize deductions.
HR 2202 prohibits federal funds from being used for gender transition procedures or health plans covering them in federal programs like Medicaid and the Affordable Care Act. It does not ban these procedures but restricts federal subsidies, requiring individuals to pay for such coverage using non-federal funds (e.g., out-of-pocket or private insurance not tied to federal programs). The bill defines gender transition procedures broadly to include hormonal treatments and surgeries (e.g., mastectomy, hysterectomy), with exceptions for medically necessary treatments related to disorders of sex development or complications from such procedures. It also clarifies that ACA premium tax credits and cost-sharing reductions cannot apply to plans covering these procedures, though separate non-federal-funded coverage remains an option.
HR 2092, the SPEAK Act of 2025, requires the Health and Human Services Secretary to create guidance for healthcare entities within one year of enactment. This guidance focuses on improving telehealth access for people with limited English proficiency, directly affecting health IT companies, hospitals, insurers, language service providers, and interpreters. Key provisions include best practices for using interpreters during video appointments, providing multilingual patient materials (like appointment reminders and prescriptions), and making digital health portals accessible. The bill aims to standardize language access in telehealth services without changing existing laws.
The PBM Price Transparency and Accountability Act requires pharmacy benefit managers (PBMs) to be more transparent about drug pricing and ensure accurate payments to pharmacies. It establishes national average drug acquisition cost benchmarks for Medicaid, prohibits PBMs from keeping excessive profits through "spread pricing," and mandates detailed reporting of drug pricing, rebates, and fees. The bill affects Medicaid programs, Medicare Part D plans, and the PBMs that negotiate drug prices on behalf of insurers. It includes enforcement mechanisms like civil penalties for non-compliance and requires PBMs to report detailed pricing information to the Secretary of Health and Human Services.
S 3267, the ASAP Act, would require Medicare to cover early detection screening tests for Alzheimer's disease and related dementias starting January 1, 2028. The bill defines these tests as FDA-cleared or approved blood, genomic, or imaging-based screenings for pre-symptomatic or early-stage detection. It directly affects Medicare beneficiaries aged 65+ who may be at risk for Alzheimer's, ensuring coverage for these specific tests once approved. The key provision adds these screenings to Medicare's payment system under Section 1833(h)(1)(A) of the Social Security Act.
This bill amends FDA review procedures to prevent delays in generic drug approvals. It requires drug companies challenging generic applications to submit a petition to the FDA within 180 days of knowing the relevant information, rather than immediately filing lawsuits. The FDA must issue a final decision on such petitions within 151 days, and courts will automatically dismiss lawsuits that skip this step or miss the 180-day deadline. These changes directly affect pharmaceutical manufacturers seeking to challenge generic drug approvals or delay their market entry.
HR 4903, the Plastic Health Research Act, directs federal agencies to fund and coordinate research on the health effects of plastic exposure, including microplastics and nanoplastics. It authorizes $10 million annually (2026-2030) for grants to academic institutions and nonprofits to develop standardized testing methods, improve research comparability, and fill gaps in understanding plastic-related health impacts. The bill also creates "Centers of Excellence" to advance this research, requiring annual public reports on findings and coordination with agencies like the EPA and FDA. This legislation directly affects researchers, federal health agencies, and public health policy by prioritizing scientific rigor in studying plastic exposure sources (e.g., food packaging, waste disposal) and health outcomes.
HR 49, the "No Pro-Abortion Task Force Act," blocks federal funding for the HHS Reproductive Healthcare Access Task Force (created January 21, 2022) and any similar successor group. It directly affects the Department of Health and Human Services by preventing the use of taxpayer money to operate this specific task force. The bill does not alter abortion laws or healthcare access; it only prohibits federal funds from supporting this particular initiative. This is a procedural funding restriction, not a policy change on reproductive healthcare.
